reports
- Dave Nicoski
- Ross LaDuke
TWI TITAN INTERNATIONAL INC.
TRIP TRIPADVISOR INC.
TITN TITAN MACHINERY
SLP SIMULATIONS PLUS
RYI RYERSON HOLDING CORPORATION
QCOM QUALCOMM INC
PCRX PACIRA BIOSCIENCES INC.
MOS MOSAIC COMPANY
J7Z JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY
IVZ INVESCO LTD.
IART INTEGRA LIFESCIENCES HOLDINGS CORPORATION
DLTR DOLLAR TREE INC.
DDD 3D SYSTEMS CORPORATION
CERS CERUS CORP.
AVD AMERICAN VANGUARD
ANIP ANI PHARMACEUTICALS INC.
AGCO AGCO CORPORATION
UPS UNITED PARCEL SERVICE INC. CLASS B
OSTK OVERSTOCK.COM INC.
GDEN GOLDEN ENTERTAINMENT
FRX_CN FENNEC PHARMACEUTICALS
ODEL.N0000 ODEL PLC
BRKS BROOKS AUTOMATION INC.
CCV COUNTERPATH
TDC TERADATA CORPORATION
BHF BRIGHTHOUSE FINANCIAL INC.
ZS ZSCALER INC.
TENB TENABLE HOLDINGS
SIBN SI-BONE
PINS PINTEREST INC. CLASS A
VIAC VIACOMCBS INC. CLASS B
ORIC ORIC PHARMACEUTICALS
THRY THRYV HOLDINGS
CERT CERTARA
ONTF ON24
SMTI SANARA MEDTECH
SDGR SCHRODINGER
COUR COURSERA INC
BBWI BATH & BODY WORKS INC
DH DEFINITIVE HEALTHCARE CORP
VERV VERVE THERAPEUTICS INC
PTLO PORTILLOS INC
DCGO DOCGO INC
EHAB ENHABIT INC
SVV SAVERS VALUE VILLAGE INC
QIPT PATIENT HOME MONITORING CORP
HUM HAMILTON U.S. MID-CAP FINANCIALS ETF
CXM SPRINKLR INC
- Dave Nicoski
- Ross LaDuke
ZBH ZIMMER BIOMET HOLDINGS INC.
SLB.N SCHLUMBERGER NV
CNHI CNH INDUSTRIAL NV
WBA WALGREENS BOOTS ALLIANCE INC
ULTA ULTA BEAUTY INC
SLP SIMULATIONS PLUS
PCRX PACIRA BIOSCIENCES INC.
PBF PBF ENERGY INC. CLASS A
IART INTEGRA LIFESCIENCES HOLDINGS CORPORATION
HXL HEXCEL CORPORATION
DAN DANA INCORPORATED
CVI CVR ENERGY INC.
AGCO AGCO CORPORATION
ACAD ACADIA PHARMACEUTICALS INC.
ALV ALLIANZ SE
MUR MURPHY OIL CORPORATION
BRKS BROOKS AUTOMATION INC.
HP HELMERICH & PAYNE INC.
PTEN PATTERSON-UTI ENERGY INC.
VLO VALERO ENERGY CORPORATION
HI HILLENBRAND INC.
INGR-R-A INGRA D.D.
EYE NATIONAL VISION HOLDINGS
CPRI CAPRI HOLDINGS LIMITED
TW TRADEWEB MARKETS INC. CLASS A
REEMF RARE ELEMENT RESOURCES
NVST ENVISTA HOLDINGS
PGNY PROGYNY
CERT CERTARA
VAL VALARIS LTD
BBWI BATH & BODY WORKS INC
CIVI CIVITAS RESOURCES INC
INVX INNOVEX INTERNATIONAL INC
Simulations Plus and Enabling Technologies Consortium Announce Strateg...
RESEARCH TRIANGLE, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has entered a new funded collaboration with the Enabling Technologies Consortium (ETC). This partnership is aimed at advancing in vitro-in vivo correlation (IVIVC) approaches for oral drug delivery and expanding the functionality of the GastroPlus platform. The collaboration focuses on enhancing the predictive capabiliti...
Simulations Plus Supported Development of Every FDA-Approved Drug in 2...
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today highlighted its impact on the pharmaceutical industry through supporting the development of 100% of the . “For more than 25 years, our clients have entrusted us to provide the mission-critical software and services needed to develop therapies that are changing the landscape of healthcare,” said , Chief Executive Officer at Simulations Plu...
Simulations Plus Reports First Quarter Fiscal 2025 Financial Results
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its first quarter fiscal 2025, ended November 30, 2024. First Quarter 2025 Financial Highlights (compared to first quarter 2024) Total revenue increased 31% to $18.9 million Software revenue increased 41% to $10.7 million, representing 57% of total revenue Services revenue incr...
Simulations Plus Announces First Quarter Fiscal Year 2025 Earnings and...
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that it will report first quarter fiscal 2025 financial results after the market close on Tuesday, January 7, 2025. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcas...
Simulations Plus to Participate in the BTIG Digital Health Forum
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in the virtual BTIG Digital Health Forum on Monday, November 25, 2024. Mr. O’Connor will join a panel discussion entitled “Supporting Drug Development, Clinical Trials, and Biopharma” at 2:00 p.m. Eastern Time. In addition, Mr. O’Connor will host one-on-one meetings through...
Simulations Plus and the University of Connecticut Receive New FDA Gra...
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has been awarded a newly funded grant from the U.S. Food and Drug Administration (FDA) to use physiologically based pharmacokinetic (PBPK) approaches in to build and validate mechanistic in vitro-in vivo correlations (IVIVCs) for long-acting injectable (LAI) technologies through a joint proposal with the University of Connecticut’s School of Pharmac...
Simulations Plus to Participate in the Stephens Annual Investment Conf...
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in a fireside chat at the Stephens Annual Investment Conference in Nashville, TN, on Wednesday, November 20, 2024, at 12:00 p.m. Eastern Time. In addition, Mr. O’Connor will host one-on-one meetings with investors throughout the day. The live audio webcast of Mr. O’Connor’s...
Simulations Plus and Partners Awarded New FDA Grant to Validate In Vit...
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced a newly funded grant from the U.S. Food and Drug Administration (FDA), secured in partnership with the University of Strathclyde and InnoGI Technologies. The project is expected to improve the understanding of amorphous solid dispersion (ASD) formulations in different conditions and predict the impact of food and pH-dependent drug-drug interactions (DDIs) th...
Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Resu...
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its fourth quarter and fiscal 2024, ended August 31, 2024. Fourth Quarter 2024 Financial Highlights (compared to fourth quarter 2023) Total revenue increased 19% to $18.7 million Software revenue increased 6% to $9.9 million, representing 53% of total revenue Services revenue increased 39% to $8.8 million, re...
Simulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earning...
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report fourth quarter and fiscal 2024 financial results after the market close on Wednesday, October 23, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering . The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this ...
Simulations Plus and the University of Southern California Secure NIH ...
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the award of a new research grant from the National Institutes of Health (NIH), secured in partnership with the University of Southern California (USC) Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences. The grant will be used to evaluate novel computational methods that account for water-ligand interactions in drug discovery and that integrate wi...
Simulations Plus to Participate in the Morgan Stanley 22nd Annual Glob...
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference at the Marriott Marquis New York, on Friday, September 6, 2024. Mr. O’Connor will host one-on-one and small group meetings throughout the day. This event is expected to include more than 200 companies as well ...
Simulations Plus Optimizes Business Unit Structure to Support Future G...
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced the optimization of its business unit and leadership structure to support future growth following the Company’s recent acquisitions. These actions will be effective August 30, 2024. “Over the past year, we made two key acquisitions, including the largest in our corporate history,” said Shawn O’Connor, Chief Executive Officer. “As a r...
Simulations Plus Releases DILIsym® X
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, has released the latest version of its flagship quantitative systems toxicology (QST) platform, version X. “Modeling and predictions regarding drug efficacy are critical in the drug development process—but so are predictions regarding safety,” said , President of Quantitative Systems Pharmacology (QSP) Solutions at Simulations Plus. “We know there is often a gap between ...
Simulations Plus Releases ADMET Predictor® Version 12
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced the release of version 12.0 of (AP12), its flagship machine learning (ML) modeling platform for the discovery, design, and optimization of new molecules. AP12 includes: Enhanced Models: New and expanded models offer greater predictive accuracy, with an average 30% increase in training set sizes, for microsome and hepatocyte clearance, protein binding, ...
Simulations Plus to Participate in KeyBanc’s 25th Annual Technology Le...
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will attend KeyBanc Capital Markets’ 25th Annual Technology Leadership Forum on Monday, August 5, 2024, in Vail, Colorado. In addition to hosting one-on-one meetings throughout the day, Mr. O’Connor will join a panel discussion entitled “AI and Digital Solutions for Drug Discovery” followed...
Simulations Plus Announces New Research Project with the International...
LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced a newly funded research project with the International Collaboration on Cosmetics Safety (ICCS) to evaluate the use of physiologically-based kinetic (PBK) modeling approaches to advance animal-free science for cosmetics and other non-pharmaceutical ingredients. In a competitive bidding process, Simulations Plus was selected for its proposal to establish wo...
Simulations Plus Reports Third Quarter Fiscal 2024 Financial Results
LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today reported financial results for its third quarter fiscal 2024, ended May 31, 2024. Third Quarter 2024 Financial Highlights (compared to third quarter 2023) Total revenue increased 14% to $18.5 million Software revenue increased 12% to $11.9 million, representing 64% of total revenue Services revenue increased 18% to $6.6 million, repre...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.